Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke


Phase 2 Results

Summary of Purpose

The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 7 April 2014.

1 Feb 2009 13 Jan 2009 1 Nov 2010 1 Nov 2010 1 Apr 2014 5 Jan 2014
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment


Not available